[go: up one dir, main page]

WO2013020079A3 - Conjugates of an il-11 moiety and a polymer - Google Patents

Conjugates of an il-11 moiety and a polymer Download PDF

Info

Publication number
WO2013020079A3
WO2013020079A3 PCT/US2012/049582 US2012049582W WO2013020079A3 WO 2013020079 A3 WO2013020079 A3 WO 2013020079A3 US 2012049582 W US2012049582 W US 2012049582W WO 2013020079 A3 WO2013020079 A3 WO 2013020079A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/049582
Other languages
French (fr)
Other versions
WO2013020079A2 (en
Inventor
Deborah H. Charych
Sean M. Culbertson
Ping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of WO2013020079A2 publication Critical patent/WO2013020079A2/en
Publication of WO2013020079A3 publication Critical patent/WO2013020079A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Conjugates of an IL-1 1 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.
PCT/US2012/049582 2011-08-04 2012-08-03 Conjugates of an il-11 moiety and a polymer Ceased WO2013020079A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515113P 2011-08-04 2011-08-04
US61/515,113 2011-08-04

Publications (2)

Publication Number Publication Date
WO2013020079A2 WO2013020079A2 (en) 2013-02-07
WO2013020079A3 true WO2013020079A3 (en) 2013-04-18

Family

ID=46785781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049582 Ceased WO2013020079A2 (en) 2011-08-04 2012-08-03 Conjugates of an il-11 moiety and a polymer

Country Status (1)

Country Link
WO (1) WO2013020079A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39711A (en) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugates of an il-15 moiety and a polymer
WO2016140983A1 (en) * 2015-03-03 2016-09-09 Avalon Biologics Limited Compositions and methods for pegylated il-11
MA41957A (en) * 2015-03-11 2018-02-28 Nektar Therapeutics CONJUGATES OF A FRACTION OF IL-7 AND A POLYMER
MA47290A (en) * 2015-10-08 2019-11-27 Nektar Therapeutics COMBINATION OF SELECTIVE IL-2RBETA AGONIST AND LONG-ACTION IL-15 AGONIST
WO2018132787A1 (en) 2017-01-16 2018-07-19 Nansha Biologics (Hk) Limited Systems and methods for production of recombinant il-11 in yeast
CN108530636B (en) * 2017-03-05 2021-05-28 厦门赛诺邦格生物科技股份有限公司 Single functionalized branched polyethylene glycol
KR102798243B1 (en) 2017-05-15 2025-04-18 넥타르 테라퓨틱스 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
WO2022212362A1 (en) * 2021-03-29 2022-10-06 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1316436A (en) * 2000-04-06 2001-10-10 赵剑 Process for preparing water-soluble slow-releasing recombination protein
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US20070111240A1 (en) * 1997-07-14 2007-05-17 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11 and methods of use thereof
WO2010024557A2 (en) * 2008-08-25 2010-03-04 Viromed Co., Ltd. Biopolymer conjugates comprising an interleukin-11 analog

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5371193A (en) 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE399809T1 (en) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp METHOD FOR PRODUCING POLYMER CONJUGATES
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
DE602004029646D1 (en) 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
AU2006259225B2 (en) 2005-06-16 2012-05-31 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINS AND COMPOSITIONS CONTAINING THEREOF
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111240A1 (en) * 1997-07-14 2007-05-17 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11 and methods of use thereof
CN1316436A (en) * 2000-04-06 2001-10-10 赵剑 Process for preparing water-soluble slow-releasing recombination protein
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2010024557A2 (en) * 2008-08-25 2010-03-04 Viromed Co., Ltd. Biopolymer conjugates comprising an interleukin-11 analog

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOWLETT M ET AL: "Cytokine signalling via gp130 in gastric cancer", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 11, 1 November 2009 (2009-11-01), pages 1623 - 1633, XP026696815, ISSN: 0167-4889, [retrieved on 20090807], DOI: 10.1016/J.BBAMCR.2009.07.009 *
TAKAGI ET AL: "Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 3, 22 May 2007 (2007-05-22), pages 271 - 278, XP022087327, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.03.009 *

Also Published As

Publication number Publication date
WO2013020079A2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2015153753A3 (en) Conjugates of an il-15 moiety and a polymer
WO2013020079A3 (en) Conjugates of an il-11 moiety and a polymer
MX358399B (en) Conjugates of an il-2 moiety and a polymer.
WO2007019331A3 (en) Conjugates of a g-csf moiety and a polymer
MX2017011562A (en) Conjugates of an il-7 moiety and an polymer.
WO2014179627A3 (en) Compositions and methods for modulating hbv and ttr expression
WO2012135025A3 (en) Conjugated lipomers and uses thereof
WO2012080383A3 (en) Personal care compositions including aqueous compositions of viscoelastic surfactants and hydrophobically modified polymers
WO2012170009A3 (en) Lubricant compositions
WO2011088027A8 (en) Compounds and methods
GEP20156230B (en) Forms of rifaximin and usage thereof
EA201200617A1 (en) POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES
EP4233771A3 (en) Vulcanization composition having reduced allergenic potential
MY166898A (en) Polymer having terminal structure including plurality of reactive solicon groups, method for manufacturing same, and use for same
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
GB2475666A (en) Polymers derived from benzobis (silolothiophene) and their use as organic semiconductors
WO2011143772A9 (en) Inhibitors of hiv replication
BR112014020104A8 (en) CONJUGATED POLYMERS
WO2012031164A3 (en) Drug delivery by carbon nanotube arrays
WO2012087327A3 (en) Polymer systems
WO2014121007A3 (en) Coating compositions and articles made therefrom
WO2010039948A3 (en) Catalyst compositions and methods of making and using the same
WO2013012666A3 (en) Compounds, methods of making, and methods of use
WO2009149030A3 (en) Oral care compositions and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12753855

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12753855

Country of ref document: EP

Kind code of ref document: A2